You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pomalidomide

Showing 51 - 75 of 161
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Relapse Trial in Denver, Saint Louis, Toronto (Elotuzumab, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Denver, Colorado
  • +2 more
Oct 14, 2021

Multiple Myeloma Trial in Atlanta, Boston (ACE-011, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Atlanta, Georgia
  • +3 more
Oct 28, 2021

Multiple Myeloma Trial in United Kingdom (Pomalidomide, Dexamethasone, Cyclophosphamide)

Active, not recruiting
  • Multiple Myeloma
  • Pomalidomide
  • +2 more
  • Belfast, United Kingdom
  • +20 more
May 24, 2022

Recurrent Plasma Cell Myeloma Trial in United States (Daratumumab, Dexamethasone, Pomalidomide)

Withdrawn
  • Recurrent Plasma Cell Myeloma
  • Daratumumab
  • +2 more
  • Wichita, Kansas
  • +4 more
Jun 13, 2022

Multiple Myeloma Trial in United States (Elotuzumab, Pomalidomide, Carfilzomib)

Terminated
  • Multiple Myeloma
  • Encinitas, California
  • +5 more
Mar 15, 2022

Plasma Cell Myeloma Trial (Isatuximab (SAR650984), Cemiplimab (SAR439684), Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • Isatuximab (SAR650984)
  • +4 more
  • (no location specified)
Feb 1, 2023

Plasma Cell Myeloma Recurrent Trial in Australia, Chile (Isatuximab IV, Isatuximab SC, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma Recurrent
  • Isatuximab IV
  • +3 more
  • Salt Lake City, Utah
  • +33 more
Jan 16, 2023

Multiple Myeloma, Deletion 17P Syndrome Trial in Italy (Daratumumab, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Deletion 17P Syndrome
  • Ancona, Italy
  • +14 more
Mar 24, 2022

Relapsed, Refractory, Multiple Myeloma Trial in Guangzhou (Pomalidomide, Bendamustine, Dexamethasone)

Not yet recruiting
  • Relapsed, Refractory, Multiple Myeloma
  • Pomalidomide
  • +2 more
  • Guangzhou, Please Select, China
    Sun Yat-sen University Cancer Center
Feb 17, 2021

Multiple Myeloma Trial in Little Rock (Pomalidomide)

Completed
Has Results
  • Multiple Myeloma
  • Pomalidomide
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences, Myeloma Institute f
Mar 30, 2021

Multiple Myeloma Trial in Worldwide (JNJ-68284528, Pomalidomide, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +87 more
Jan 17, 2023

Multiple Myeloma Trial in Worldwide (Selinexor, Elotuzumab, Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Tucson, Arizona
  • +67 more
Jul 26, 2022

Relapsed/Refractory Multiple Myeloma Trial in Worldwide (AMG 701, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Relapsed/Refractory Multiple Myeloma
  • AMG 701
  • +2 more
  • Scottsdale, Arizona
  • +33 more
Nov 29, 2022

Multiple Myeloma, Amyloidosis Trial in Toronto (Lenalidomide, Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Amyloidosis
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Nov 26, 2021

Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (drug,

Terminated
Has Results
  • Multiple Myeloma-Light Chain Only
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2021

Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Elotuzumab, Pomalidomide)

Suspended
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
Oct 18, 2021

Refractory Multiple Myeloma Trial in Switzerland (Pomalidomide, Dexamethasone)

Terminated
  • Refractory Multiple Myeloma
  • Aarau, Switzerland
  • +15 more
Jun 7, 2021

Recurrent Plasma Cell Myeloma Trial in Columbus (Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis)

Completed
  • Recurrent Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jun 10, 2021

Multiple Myeloma Trial in Torino (Pomalidomide, Cyclophosphamide, Dexamethasone)

Terminated
Has Results
  • Multiple Myeloma
  • Pomalidomide
  • +2 more
  • Torino, Italy
    Fondazione EMN Italy Onlus
Feb 16, 2021

Multiple Myeloma, Recurrent or Refractory Trial in China (Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Recurrent or Refractory
  • Beijing, Beijing, China
  • +22 more
Feb 9, 2022

Plasma Cell Myeloma Trial in United States (Isatuximab SAR650984, Pomalidomide, Dexamethasone)

Completed
  • Plasma Cell Myeloma
  • Isatuximab SAR650984
  • +2 more
  • Scottsdale, Arizona
  • +12 more
Jul 8, 2021

Multiple Myeloma Trial in United States (Magrolimab, Daratumumab, Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Magrolimab
  • +5 more
  • Tucson, Arizona
  • +8 more
Jul 28, 2022

Multiple Myeloma Trial in United States (SEA-BCMA, dexamethasone, pomalidomide)

Recruiting
  • Multiple Myeloma
  • Palo Alto, California
  • +10 more
Aug 24, 2022

Multiple Myeloma Trial in Worldwide (isatuximab SAR650984 IV, pomalidomide, dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • isatuximab SAR650984 IV
  • +4 more
  • Gilbert, Arizona
  • +14 more
May 6, 2022

Multiple Myeloma Trial in Worldwide (Cevostamab, Tocilizumab, Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Duarte, California
  • +7 more
Aug 17, 2022